MissionAD is a global clinical research program testing an investigational, once-daily drug tablet for the early stages of Alzheimer’s disease. Doctors are studying the safety of this investigational drug to see if it may help people with early Alzheimer’s disease in the future. The drug is not yet approved in the U.S. or any other country, and is not available to the public.3,4
MissionAD participants will be randomly assigned to receive either the investigational drug, or placebo (an identical looking pill with no active ingredient). During the study, participants will receive study-related medical care provided by the study’s doctors and nurses, including a diagnosis and regular check-ups.
Those who participate will be expected to attend regular visits to the clinic, where healthcare professionals will closely monitor them and check for any changes in their health.
A clinical research study is a research project done with human volunteers to learn more about new investigational drugs and treatments.11
Some volunteers are interested in access to drugs or treatments, while others volunteer to help advance science. Whatever your reason for participating in clinical research, we will monitor your health and protect your privacy.
Research is critical for continuing to advance Alzheimer’s disease treatments to potentially help today’s patients and future generations.
To qualify for this study, you:
Over approximately 2 years, all MissionAD participants will make regular visits to the study doctor’s office for a total of about 15 visits. Participants will take an oral tablet each morning with or without food.
1. World Health Organization. Dementia Fact Sheet. May 2017. http://who.int/mediacentre/factsheets/fs362/en/. Accessed June 22, 2017.
2. Alzheimer’s Association. May 2014. http://alz.org/global/. Accessed June 22, 2017.
3. U.S. National Institutes of Health. A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease (MissionAD1). https://clinicaltrials.gov/ct2/show/NCT02956486. Accessed June 22, 2017.
4. U.S. National Institutes of Health. A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease (MissionAD2). https://clinicaltrials.gov/ct2/show/NCT03036280. Accessed June 22, 2017.
5. Vassar, R. BACE1 Inhibitor Drugs in Clinical Trials for Alzheimer’s Disease. Alzheimer's Research & Therapy:2014;6.89:1-14.
6. Alzheimer's Association. Mild Cognitive Impairment (MCI): Signs, Symptoms, & Diagnosis. May 2017. http://www.alz.org/dementia/mild-cognitive-impairment-mci.asp. Accessed June 22, 2017.
7. Alzheimer's Association. What Is Alzheimer's? May 2017. http://www.alz.org/alzheimers_disease_what_is_alzheimers.asp. Accessed June 22, 2017.
8. Alzheimer's Association. Stages of Alzheimer's & Symptoms. June 2017. http://www.alz.org/alzheimers_disease_stages_of_alzheimers.asp#mild. Accessed June 22, 2017.
9. Alzheimer's Association. Why Get Checked. June 2017. http://www.alz.org/alzheimers_disease_why_get_checked.asp. Accessed June 22, 2017.
10. Alzheimer's Association. Alzheimer’s and Dementia Testing for Earlier Diagnosis. June 2017. http://alz.org/research/science/earlier_alzheimers_diagnosis.asp. Accessed June 22, 2017.
11. National Institutes of Health. What Are Clinical Trials? May 2017. https://www.nhlbi.nih.gov/studies/clinicaltrials. Accessed June 22, 2017.